Literature DB >> 15690162

[TNFalpha inhibitors in the treatment of uveitis].

K Greiner1, J Plskova.   

Abstract

Tumor necrosis factor alpha (TNFalpha) is a pleiotropic cytokine that plays a pivotal role in chronic inflammatory diseases. Data from animal experiments indicate that TNFalpha is an important part of the pro-inflammatory processes in non-infectious uveitis. Neutralization of TNFalpha with TNF receptor fusion proteins or monoclonal antibodies, therefore, represents a promising strategy for the treatment of uveitis. In addition, the currently available TNFalpha inhibitors demonstrate a favourable profile of side effects compared to conventional immunosuppressive agents. Previous studies showed the immunological efficacy of TNFalpha inhibitors in the treatment of posterior uveitis. However, the available data on anterior uveitis are inconclusive with respect to the clinical efficacy of these agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690162     DOI: 10.1007/s00347-004-1165-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  25 in total

Review 1.  Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors.

Authors:  O Kaipiainen-Seppänen; M Leino
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

2.  Long-term outcome of etanercept therapy in children with treatment-refractory uveitis.

Authors:  Andreas Reiff
Journal:  Arthritis Rheum       Date:  2003-07

3.  Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis.

Authors:  A D Dick; L Duncan; G Hale; H Waldmann; J Isaacs
Journal:  J Autoimmun       Date:  1998-06       Impact factor: 7.094

4.  Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis.

Authors:  M Santos Lacomba; C Marcos Martín; J M Gallardo Galera; M A Gómez Vidal; E Collantes Estévez; R Ramírez Chamond; M Omar
Journal:  Ophthalmic Res       Date:  2001 Sep-Oct       Impact factor: 2.892

Review 5.  Regulation of ocular inflammation--what experimental and human studies have taught us.

Authors:  M D de Smet; C C Chan
Journal:  Prog Retin Eye Res       Date:  2001-11       Impact factor: 21.198

Review 6.  Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Authors:  Hyon J Kwon; Timothy R Coté; Michael S Cuffe; Judith M Kramer; M Miles Braun
Journal:  Ann Intern Med       Date:  2003-05-20       Impact factor: 25.391

7.  Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

Authors:  Frederick Wolfe; Kaleb Michaud; Janice Anderson; Kathy Urbansky
Journal:  Arthritis Rheum       Date:  2004-02

8.  Induction of autoantibodies during prolonged treatment with infliximab.

Authors:  Mariam Louis; Joyce Rauch; Mary Armstrong; Mary-Ann Fitzcharles
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

Review 9.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Authors:  Stephen J Jarrett; Gaye Cunnane; Philip G Conaghan; Sarah J Bingham; Maya H Buch; Mark A Quinn; Paul Emery
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.